S. Maira

发表

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.

M. Wilkerson, H. Ji, Kwok-Kin Wong, 2010, Cancer cell.

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

W. Sellers, D. Fabbro, Christopher J. Wilson, 2011, Molecular Cancer Therapeutics.

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014, Molecular Cancer Therapeutics.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Daniela Gabriel, Doriano Fabbro, Pascal Furet, 2008, Molecular Cancer Therapeutics.

Net-b, a Ras-insensitive factor that forms ternary complexes with serum response factor on the serum response element of the fos promoter

B. Wasylyk, S. Maira, A. Ayadi, 1997, Molecular and cellular biology.

mTOR Inhibitor RAD 001 ( Everolimus ) Has Antiangiogenic / Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

H. Lane, C. Schnell, J. Brueggen, 2009 .

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity

M. Yoshimura, R. Muschel, E. Fokas, 2012, Radiation Oncology.

Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells

B. Solomon, G. McArthur, P. Neilsen, 2011, Molecular Cancer Research.

Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

M. Loda, S. Signoretti, T. Roberts, 2013, Cancer discovery.

The Net Repressor Is Regulated by Nuclear Export in Response to Anisomycin, UV, and Heat Shock

A. Dierich, B. Wasylyk, S. Maira, 1999, Molecular and Cellular Biology.

Abstract 350: NVP-BKM120: A selective pan-PI3 kinase inhibitor induces G2/M arrest in glioma cell lines via FOXO3a and GADD45a loop

T. Lafortune, W. Yung, C. García-echeverría, 2010 .

Abstract 4472: NVP-BKM120, a pan class I PI3K inhibitor impairs microvascular permeability and tumor growth as detected by DCE-MRI and IFP measurements via radio-telemetry: Comparison with NVP-BEZ235

C. Schnell, R. Cozens, C. García-echeverría, 2010 .

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

J. Tamburini, S. Maira, N. Ifrah, 2010 .

High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.

P. Lollini, C. García-echeverría, K. Scotlandi, 2010, European journal of cancer.

Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.

C. Schnell, F. Blasco, G. Caravatti, 2016, Bioorganic & medicinal chemistry letters.

Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells

H. Lane, S. Maira, D. Benjamin, 2018, Cell reports.

Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery.

C. García-echeverría, C. Voliva, S. Maira, 2008, Expert opinion on therapeutic targets.

Abstract 3748: NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anti-cancer agent

C. Schnell, F. Hofmann, S. Brachmann, 2012 .

PTEN-deficient cancers depend on PIK3CB

Alice T. Loo, D. Wiederschain, F. Stegmeier, 2008, Proceedings of the National Academy of Sciences.

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.

Simon Ng, Yanchen Zhang, Kenneth Crawford, 2011, ACS medicinal chemistry letters.

Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter.

B. Wasylyk, J. Hagman, W. Wheat, 1996, Genes & development.

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

G. Mills, M. Dowsett, J. Balko, 2011, Cancer discovery.

Reduced pathological angiogenesis and tumor growth in mice lacking GPR4, a proton sensing receptor

E. Billy, C. Schnell, M. Ferretti, 2011, Angiogenesis.

ERa-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

G. Mills, M. Dowsett, J. Balko, 2011 .

Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

G. Mills, M. Dowsett, J. Balko, 2011 .

Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

W. Yung, T. Lafortune, D. Koul, 2011, Clinical Cancer Research.

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

W. Sellers, A. Kauffmann, F. Hofmann, 2012, Molecular Cancer Therapeutics.

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

Jing Yuan, William R. Sellers, Christoph Lengauer, 2010, Science Translational Medicine.

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Kwok-Kin Wong, J. Engelman, R. Bronson, 2009, Proceedings of the National Academy of Sciences.

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

H. Lane, C. Schnell, C. García-echeverría, 2009, Proceedings of the National Academy of Sciences.

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.

C. Schnell, R. Cozens, C. García-echeverría, 2008, Cancer research.

Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery

C. García-echeverría, C. Voliva, S. Maira, 2008, Expert opinion on therapeutic targets.

The ternary complex factor Net contains two distinct elements that mediate different responses to MAP kinase signalling cascades

Bohdan Wasylyk, B. Wasylyk, S. Maira, 2000, Oncogene.

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.

P. Furet, S. Maira, F. Stauffer, 2009, Future medicinal chemistry.

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

P. Schultz, C. García-echeverría, V. Reddy, 2009, Proceedings of the National Academy of Sciences.

Heat shock protein 70-mediated sensitization of cells to apoptosis by Carboxyl-Terminal Modulator Protein

B. Hemmings, D. Brazil, Jongsun Park, 2009, BMC Cell Biology.

Identification and characterization of NVP-BKM 120 , an orally available pan class I PI 3-Kinase inhibitor

W. Sellers, D. Fabbro, R. Schlegel, 2011 .

Net, a negative Ras‐switchable TCF, contains a second inhibition domain, the CID, that mediates repression through interactions with CtBP and de‐acetylation

B. Wasylyk, S. Maira, Catherine Ducret, 1999, The EMBO journal.

Net, a new ets transcription factor that is activated by Ras.

B. Wasylyk, A. Pintzas, S. Maira, 1994, Genes & development.

Carboxyl-Terminal Modulator Protein (CTMP), a Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane

Brian A. Hemmings, S. Kaech, B. Hemmings, 2001, Science.

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells

Valsamo Anagnostou, Robert Camp, G. Bepler, 2012, PloS one.

PI3K inhibitors for cancer treatment: where do we stand?

C. Schnell, C. García-echeverría, S. Maira, 2009, Biochemical Society transactions.

From wortmannin and LY 294002 : the path towards clinical candidates for PI 3 K inhibition

C. Schnell, C. García-echeverría, S. Maira, 2009 .

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.

P. Furet, C. García-echeverría, S. Maira, 2008, Bioorganic & medicinal chemistry letters.

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

C. Schnell, C. García-echeverría, B. Giese, 2009, Molecular Cancer Research.

Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.

R. Bronson, Jean J. Zhao, S. Maira, 2013, Genes & development.

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity

M. Yoshimura, R. Muschel, E. Fokas, 2012, Radiation oncology.

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.

R. Muschel, J. Im, E. Fokas, 2012, Cancer research.

Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014 .

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

W. Yung, T. Liu, T. Lafortune, 2009, Molecular Cancer Therapeutics.

Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.

W. Sellers, E. Billy, C. Schnell, 2016, Cancer research.

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

N. Munshi, D. McMillin, Jake E. Delmore, 2009, Cancer research.

A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

G. Mills, L. Cantley, R. Bronson, 2014, Cancer research.

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

T. Roberts, Jean J. Zhao, S. Maira, 2014, The Journal of clinical investigation.

The transcription factor Net regulates the angiogenic switch.

J. Schalken, B. Wasylyk, J. Abecassis, 2003, Genes & development.

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

H. Lane, G. Martiny-Baron, C. Schnell, 2009, Clinical Cancer Research.

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

J. Tamburini, S. Maira, N. Ifrah, 2010, Clinical Cancer Research.

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

W. Sellers, T. Roberts, F. Hofmann, 2012, PloS one.

Domain Swapping Used To Investigate the Mechanism of Protein Kinase B Regulation by 3-Phosphoinositide-Dependent Protein Kinase 1 and Ser473 Kinase

Brian A. Hemmings, Peter J. Parker, M. Andjelkovic, 1999, Molecular and Cellular Biology.

Negative Regulation of ERK and Elk by Protein Kinase B Modulates c-fos Transcription*

M. Andjelkovic, B. Hemmings, S. Maira, 2003, The Journal of Biological Chemistry.

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

N. Ostermann, C. Schnell, Toshio Shimizu, 2022, Cancer discovery.

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

E. Giang, F. Paris, S. Maira, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Reversion of Ras transformed cells by Ets transdominant mutants.

B. Wasylyk, S. Maira, C. Wasylyk, 1994, Oncogene.

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

D. Hedley, C. García-echeverría, S. Maira, 2009, British Journal of Cancer.

Net (ERP/SAP2) one of the Ras‐inducible TCFs, has a novel inhibitory domain with resemblance to the helix‐loop‐helix motif.

B. Wasylyk, J. Wurtz, S. Maira, 1996, The EMBO journal.

Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

M. Loda, S. Signoretti, T. Roberts, 2013, Cancer discovery.

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

Michael P. Morrissey, W. Sellers, J. Monahan, 2010, Science Translational Medicine.

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

C. Schnell, C. García-echeverría, B. Giese, 2009, Molecular Cancer Research.